CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

23 February 2024 - Positive CHMP opinion is based on pivotal Phase 3 PROTECT study results. ...

Read more →

Highlights from the 19-22 February 2024 CHMP meeting

23 February 2024 - The EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting. ...

Read more →

First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria

23 February 2024 - The EMA has recommended granting a marketing authorisation in the European Union for Voydeya, the first ...

Read more →

Bristol Myers Squibb receives positive CHMP opinion for Reblozyl (luspatercept) for treatment of adults with transfusion-dependent anaemia due to low- to intermediate-risk myelodysplastic syndromes

23 February 2024 - In the pivotal Phase 3 COMMANDS study, Reblozyl nearly doubled the percentage of patients achieving primary ...

Read more →

Merck receives positive EU CHMP opinion for Keytruda (pembrolizumab) in combination with chemotherapy as neo-adjuvant treatment, then continued as monotherapy as adjuvant treatment, for the treatment of resectable NSCLC at high risk of recurrence

23 February 2024 - Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial. ...

Read more →

A cancer doctor’s view of why reform of PHARMAC is vital

23 February 2024 - Late last year, many of my colleagues returned from the largest international gathering of doctors who ...

Read more →

Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE

22 February 2024 - Thousands of people with severe hair loss due to alopecia areata are set to benefit from a ...

Read more →

Terminally ill patients despair amid price war over CAR-T cancer therapy

22 February 2024 - Australia risks “being pushed to the back of the queue” of countries to gain access to ...

Read more →

Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)

21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...

Read more →

EMA publishes agenda for 19-22 February 2024 CHMP meeting

19 February 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

Updates to the HTA review research and analysis papers collection: emerging health technologies

15 February 2024 - The draft paper 'Emerging Health Technologies' developed to support the deliberations of the HTA Review Reference ...

Read more →

SMC - February 2024 decisions

12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

House of Representatives passes bill to ban use of QALYs in federally funded health care programs

12 February 2024 - The U.S. House of Representatives passed H.R. 485, the Protecting Health Care for All Patients Act, this ...

Read more →

Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma

9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...

Read more →

Olaparib in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer

7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone ...

Read more →